SCHEMBL27066401

SCHEMBL27066401

CSCC[C@H](NC=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)NC(Cc1ccc(O)cc1)C(=O)NC(Cc1ccc(O)cc1)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 1/20 0.56
NPY4R P50391 4/20 0.54
NPY1R P25929 3/20 0.54
NPY2R P49146 3/20 0.54
FPR1 P21462 4/20 0.54
FPR2 P25090 4/20 0.54
ACE P12821 4/20 0.50
FNTA P49354 3/20 0.49
FNTB P49356 3/20 0.49
MME P08473 1/20 0.47
CPA1 P15085 1/20 0.47
ACE2 Q9BYF1 1/20 0.47
NPY5R Q15761 2/20 0.46
IL1RN P18510 1/20 0.46
ERAP2 Q6P179 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27066381 1.00 FOLH1 (0.56) FOLH1NPY4RNPY1RNPY2RFPR1
SCHEMBL27066379 1.00 FOLH1 (0.56) FOLH1NPY4RNPY1RNPY2RFPR1
SCHEMBL1695336 0.99 FOLH1 (0.57) FOLH1NPY4RNPY1RNPY2RFPR1
SCHEMBL1695337 0.99 FOLH1 (0.57) FOLH1NPY4RNPY1RNPY2RFPR1
SCHEMBL27066400 0.97 FPR1 (0.56) FOLH1NPY4RNPY1RNPY2RFPR1
SCHEMBL27066357 0.97 FPR1 (0.56) FOLH1NPY4RNPY1RNPY2RFPR1
SCHEMBL27066371 0.97 FPR1 (0.56) FOLH1NPY4RNPY1RNPY2RFPR1
SCHEMBL27066398 0.97 FPR1 (0.56) FOLH1NPY4RNPY1RNPY2RFPR1
SCHEMBL27066369 0.97 FPR1 (0.56) FOLH1NPY4RNPY1RNPY2RFPR1
SCHEMBL27066397 0.97 FPR1 (0.56) FOLH1NPY4RNPY1RNPY2RFPR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240024409-A1 N-f-MLF DERIVATIVES THAT INHIBIT FORMYL PEPTIDE RECEPTORS FOR THE TREATMENT OF DISEASE UNIVERSITY OF SOUTH ALABAMA (US) 2024-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240024409-A1 N-f-MLF DERIVATIVES THAT INHIBIT FORMYL PEPTIDE RECEPTORS FOR THE TREATMENT OF DISEASE FPR1, FPR2, FPR3 FOLH1 325/4885NPY4R 180/4885NPY1R 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.